Arvinas received FDA approval for Veppanu (vepdegestrant) in May 2026, marking the first FDA-approved PROTAC protein degrader for treating ESR1-mutated breast cancer. The company out-licensed global rights to Rigel Pharmaceuticals for $70 million upfront plus up to $320 million in milestones and royalties. Arvinas' diversified pipeline includes candidates for lymphoma, Parkinson's disease, and solid tumors with data expected through 2027.

Arvinas announced the first patient dosing in a Phase 1/2 clinical trial of ARV-6723, an oral PROTAC designed to degrade HPK1 for advanced solid tumors. The drug is Arvinas' first immuno-oncology candidate and the first HPK1 PROTAC degrader to enter clinical trials in the US. Preclinical data showed potent HPK1 degradation, enhanced immune activity, and antitumor effects as monotherapy and in combination with anti-PD-1 therapy, including activity in anti-PD-1-resistant models.

Knight Therapeutics announced that it received regulatory approval from Colombia's health authority (INVIMA) for TAVALISSE (fostamatinib disodium hexahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The company plans to launch the drug in Colombia in the first half of 2027, following its May 2026 launch in Mexico and an expected Q4 2026 launch in Brazil.

Knight Therapeutics Inc. (TSX: GUD) announced regulatory approval from Colombia's INVIMA for TAVALISSE® (fostamatinib disodium heptahydrate) to treat adult patients with chronic immune thrombocytopenia (ITP). The approval marks a significant milestone in Knight's Latin American expansion strategy following its 2022 licensing agreement with Rigel Pharmaceuticals. The company plans to launch TAVALISSE in Colombia in H1 2027, following launches in Mexico (May 2026) and Brazil (Q4 2026).

Onco360, the nation's leading independent specialty pharmacy, has been selected as a pharmacy partner by Rigel Pharmaceuticals for VEPPANU (vepdegestrant), an FDA-approved PROTAC estrogen receptor degrader for treating ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 VERITAC-2 trial, vepdegestrant demonstrated a 43% reduction in disease progression or death risk compared to fulvestrant in patients with ESR1 mutations.

Rigel Pharmaceuticals announced an exclusive global licensing agreement with Arvinas and Pfizer for VEPPANU (vepdegestrant), an oral PROTAC drug for ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. Rigel will contribute up to $40 million toward development over four years and pursue U.S. and global commercialization rights. The drug received FDA approval in May 2026, showing a 43% reduction in disease progression or death risk compared to fulvestrant in the Phase 3 VERITAC-2 trial.

Rigel Pharmaceuticals exceeded Q2 2025 financial expectations with 176.4% revenue growth, driven by strong product sales and a significant Eli Lilly collaboration, raising full-year revenue guidance to $270-$280 million.

Knight Therapeutics, a specialty pharmaceutical company, announced that its Mexican subsidiary has obtained regulatory approval from COFEPRIS for TAVALISSE® (fostamatinib) to treat adult patients with chronic immune thrombocytopenia (ITP) whose response to prior treatment was insufficient.

The article discusses the T-cell lymphoma drug pipeline, highlighting the development of novel therapies by companies like Eisai, Takeda, and Rhizen Pharmaceuticals. Regulatory agencies are providing support to accelerate the development of these treatments, addressing the urgent need for better options in this challenging condition.

Rigel (RIGL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Rigel (RIGL) delivered earnings and revenue surprises of -66.67% and 5.58%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs (PRPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.